Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2015.04.097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of clopidogrel and ticagrelor in acute coronary syndrome patients with loss-of-function alleles after percutaneous coronary intervention: based on the Global Registry of Acute Coronary Events score.
Res Pract Thromb Haemost
August 2025
Department of Cardiology, State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China.
Background: The selection of P2Y12 inhibitors for acute coronary syndrome patients after percutaneous coronary intervention (PCI) remains controversial among East Asian patients.
Objectives: This study aimed to identify the optimal P2Y12 inhibitor selection for the East Asian population carrying loss-of-function (LOF) alleles based on the Global Registry of Acute Coronary Events (GRACE) score.
Methods: Between March 2016 and March 2019, a cohort of 8683 patients diagnosed with acute coronary syndrome who survived PCI were enrolled in this study.
Interaction of CYP2C19 with the effect of clopidogrel in secondary prevention of major ischemic events: systematic review and meta-analysis.
Int J Stroke
August 2025
Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Background And Aims: Clopidogrel may be a less effective antiplatelet agent for secondary prevention after cardiovascular events in carriers of the CYP2C19 Loss of Function (LoF) allele. Randomized controlled trials (RCTs) of clopidogrel in patients with known CYP2C19 carrier status have provided inconsistent results. This meta-analysis aims to pool evidence on the effect of different antiplatelet strategies on outcomes according to CYP2C19 LoF status.
View Article and Find Full Text PDFObjective: To compare the efficacy and safety of ticagrelor versus clopidogrel in stroke patients who were loss-of-function (LOF) carriers stratified by age and renal function.
Methods: Patients in the CHANCE-2 trial were randomized to ticagrelor-aspirin or clopidogrel-aspirin treatment. The primary efficacy outcome was occurrence of a new stroke within 90 days, while bleeding was assessed for safety.
Advances in the Clinical Use of Clopidogrel: A Review of Individualized Treatment Strategies and Monitoring Optimization Based on Genetic Polymorphisms.
Pharmgenomics Pers Med
July 2025
Department of Pharmacy, Hebei Petrochina Central Hospital, Langfang, Hebei, People's Republic of China.
This paper systematically reviews recent advances in clopidogrel clinical applications to optimize therapeutic precision and medication safety. Using a literature review methodology, we elucidate clopidogrel's pharmacokinetic properties and pharmacodynamic mechanisms, while evaluating its clinical efficacy and adverse reactions in disease management. Recent studies have emphasized the key role of genetic polymorphisms in regulating the efficacy and safety of clopidogrel.
View Article and Find Full Text PDFComparison between clopidogrel and ticagrelor in CYP2C19 loss-of-function alleles coronary artery disease and stroke patients: a meta-analysis.
Eur J Clin Pharmacol
September 2025
Department of Total Parenteral Nutrition, Alexandria Main University Hospital, Alexandria, Egypt.
Background: It is suggested that in patients with coronary artery diseases (CAD) and stroke, the use of ticagrelor and aspirin may perform better than clopidogrel and aspirin regarding the risk of thrombosis/embolism, including recurrent myocardial infarction (MI) and cardiovascular death, especially in those carrying CYP2C19 loss-of-function (LOF) alleles. Therefore, we conducted the present systematic review and meta-analysis to investigate the effect of clopidogrel and ticagrelor in CAD and stroke patients with CYP2C19 LOF alleles (poor metabolizers of clopidogrel).
Methods: We performed the current systematic review and meta-analysis by searching for all eligible publications on PubMed, Web of Science, and Scopus from inception to November 2024.